Yes, the current corporate presentation uses this number as an average ($USD 50,000 to $USD 150,000) to estimate an NMIBC market opportunity of $USD 5 Billion annually. See page 7.

https://theralase.com/wp-content/uploads/2022/07/Presentation-2022.pdf

ScienceFirst wrote: TLT once mentioned 100K$US, just a bit below Keytruda cost.  Enough profitability, while being just below KEYTRUDA cost, but with less treatments and higher efficacy.